Neurocrine Biosciences (NBIX) Non Operating Income (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Non Operating Income of $10.7 million for Q2 2026, down 23.02% year-over-year from $13.9 million in Q2 2025, and down 79.96% on a QoQ basis from $53.4 million in Q1 2026.
Neurocrine Biosciences (NBIX) Non Operating Income (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Non Operating Income for 17 years, with the latest figure at $10.7 million in Q2 2026.
- Non Operating Income for Q2 2026 came in at $10.7 million, down 23.02% year-over-year; the trailing twelve-month figure through Jun 2026 was $145.4 million (up 352.96% YoY), and the FY2025 annual result was $86.3 million, up 202.13% from the prior year.
- Non Operating Income declined to $10.7 million in Q2 2026, from $53.4 million in the prior quarter.
- Over five years, Non Operating Income peaked at $53.4 million in Q1 2026 and troughed at -$78.0 million in Q2 2022.
- A 5-year average of $6.2 million and a median of $12.4 million in 2023 frame the typical range for Non Operating Income.
- The widest annual swing landed in 2022, when Non Operating Income plunged 1371.7%; it then jumped 712.31% in 2025.
- A 5-year view of Non Operating Income shows it stood at $14.5 million in 2022, then soared by 230.34% to $47.9 million in 2023, then slumped by 56.99% to $20.6 million in 2024, then soared by 38.35% to $28.5 million in 2025, then plunged by 62.46% to $10.7 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were $10.7 million in Q2 2026, $53.4 million in Q1 2026, and $28.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | -20.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.70 Mn |
| Mar 31, 2026 | 53.40 Mn |
| Dec 31, 2025 | 28.50 Mn |
| Sep 30, 2025 | 52.80 Mn |
| Jun 30, 2025 | 13.90 Mn |
| Mar 31, 2025 | -8.90 Mn |
| Dec 31, 2024 | 20.60 Mn |
| Sep 30, 2024 | 6.50 Mn |
| Jun 30, 2024 | -46.80 Mn |
| Mar 31, 2024 | -64.80 Mn |
| Dec 31, 2023 | 47.90 Mn |
| Sep 30, 2023 | -25.60 Mn |
| Jun 30, 2023 | 48.00 Mn |
| Mar 31, 2023 | 10.90 Mn |
| Dec 31, 2022 | 14.50 Mn |
| Sep 30, 2022 | 10.10 Mn |
| Jun 30, 2022 | -78.00 Mn |
| Mar 31, 2022 | 18.30 Mn |
| Dec 31, 2021 | 22.50 Mn |
| Sep 30, 2021 | -14.00 Mn |